Get started
Markets US Stocks Health Technology Biotechnology

NuCana plc

NCNA NASDAQ
NCNA
NuCana plc NASDAQ
See more on advanced chartSee more on advanced chart
 
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
Ideas Financials Technicals

NCNA Depositary Receipt Chart

Ideas

Videos only
This NCNA Penny Stock Could Surge Over 300%, Say Analyst
NCNA
, 60
NCNA: This NCNA Penny Stock Could Surge Over 300%, Say Analyst

This NCNA Penny Stock Could Surge Over 300%, Say Analyst NuCana uses a phosphoramidate chemistry technology called ProTide to create a class of drugs that will surmount the limitations of the existing nucleotide analogs behind many chemotherapy drugs. NuCana’s ProTides have already been used in Gilead’s antiviral drug Sovaldi. In May of last year, NuCana...

waiting the breakout
NCNA
, 1D
Long
NCNA: waiting the breakout

Not a High Quality Trade!

NCNA Buy up
NCNA
, 1D
Long
NCNA: NCNA Buy up

up

Short selling
NCNA
, 1D Short
NCNA: Short selling

down

NCNA - Joining Havard Endowment Fund - Buying some here
NCNA
, 1D
Long
NCNA: NCNA - Joining Havard Endowment Fund - Buying some here

...

NCNA Bullish Divergence
NCNA
, 3D
NCNA: NCNA Bullish Divergence

Looking like a possible buy opportunity. Showing bullish divergence. I'm waiting for the stochastic RSI to cross 20 on the 3 day.

NuCana Announces FDA Clearance to Commence Phase III Study of Ac
NCNA
, D
Long
NCNA: NuCana Announces FDA Clearance to Commence Phase III Study of Ac

NCNA: NuCana plc 2019-10-25 07:00:05 NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

NCNA, Daily
NCNA
, 1D
NCNA: NCNA, Daily

waiting for confirmation signe , on 4H frame hammer candle was formed

Technicals

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Biotechnology
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Breaking news